Save on Risankizumab-RZAA with Coupons, Discounts & Savings Programs

Risankizumab-RZAA is available as follows:

• Subcutaneous injection
• 150 mg/mL in each single-dose prefilled pen
• 90 mg/mL in each single-dose prefilled syringe
• 150 mg/mL in each single-dose prefilled syringe
• 180 mg/1.2 mL (150 mg/mL) in each single-dose prefilled cartridge
• 360 mg/2.4 mL (150 mg/mL) in each single-dose prefilled cartridge
• Intravenous infusion 600 mg/10 mL (60 mg/mL) in each single-dose vial

• Risankizumab-RZAA is a monoclonal antibody that is used to treat:
• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Moderate-to-severe Crohn’s disease

Risankizumab-RZAA is a monoclonal antibody that works as an interleukin antagonist. It attaches to certain proteins in your immune system called interleukin-23 (IL-23) that play a role in causing inflammation. This stops the proteins from getting turned on, which helps lower inflammation.

• Risankizumab-RZAA is dosed as follows:
• Plaque psoriasis and psoriatic arthritis: The typical starting dose is 150 mg injected under the skin once every month for the first 2 doses. Then, it’s given once every 3 months.
• Crohn’s disease: The typical starting dose is 600 mg infused through the veins (intravenous or IV) once every month for the first 3 doses. Then one month later, the dose changes to 180 mg or 360 mg injected under the skin that’s given once every 2 months.

Risankizumab-RZAA is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. Risankizumab-RZAA is contraindicated in patients with a history of serious
hypersensitivity reaction to Risankizumab-RZAA or any of the excipients.

• Common side effects of Risankizumab-RZAA:
• Upper respiratory infections
• Joint pain
• Headache
• Tiredness
• Injection site reaction (e.g., bruising, redness, pain, swelling, itching, warmth, bleeding, irritation)

Serious side effects are rare with Risankizumab-RZAA. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic reactions: difficulty breathing; hives; swelling of your face, lips, tongue, or throat
  Infection: fever; cough; difficulty breathing; diarrhea; weakness; sweating; chills; scaly, itchy, or burning skin

• There are no major drug interactions listed for Risankizumab-RZAA. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

Various FDA-approved generic manufacturers

Although there are no data on Risankizumab-RZAA, monoclonal antibodies can be actively transported across the placenta, and Risankizumab-RZAA may cause immunosuppression in the in utero-exposed infant. Risankizumab-RZAA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is a pregnancy exposure registry that monitors outcomes in women who become pregnant while treated with Risankizumab-RZAA. Patients should be encouraged to enroll by calling 1-877-302-2161 or
visiting  glow pregnancy registry 

• Skyrizi